nature portfolio

Corresponding author(s):	Valentin Borshchevskiy
Last updated by author(s):	Mar 9, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

C.			
St	·at	icti	Γ

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\times	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

For smFRET data collection we use commertial software SPCM (Becker & Hickl)

Data analysis

All analyses of experimental smFRET data were performed in the software package PAM (PIE Analysis with MATLAB)91. The software is available as a source code, requiring MATLAB to run, or as pre-compiled standalone distributions for Windows or MacOS at http://www.cup.uni-muenchen.de/pc/lamb/software/pam.html and hosted in Git repositories under http://www.gitlab.com/PAM-PIE/PAM and http://www.gitlab.com/PAM-PIE/PAMcompiled. A detailed manual is located under http://pam.readthedocs.io. The version of PAM used for the analysis of smFRET data is also available in Zenodo with the identifier https://doi.org/10.5281/zenodo.7722845.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data that support the findings of this study are available from the corresponding author upon reasonable request. The burst data from smFRET experiments and data from molecular dynamics simulations are available in Zenodo with the identifier https://doi.org/10.5281/zenodo.7722845.

Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

Reporting on sex and gender	n/a (no human participants in the study)
Population characteristics	n/a (no human participants in the study)
Recruitment	n/a (no human participants in the study)
Ethics oversight	n/a (no human participants in the study)

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.				
∑ Life sciences	Behavioural & social sciences	Ecological, evolutionary & environmental sciences		
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf				

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	no sample size calculation was performed; the arbitrary threshold of > 10 000 molecules/sample was used for smFRET data collection, because it typically allows good quality data in similar experiments
Data exclusions	no data were excluded from the analysis
Replication	the most important conclusions were confirmed with three experiments with different protein aliquotes
Randomization	randomization was not applicable because we use identical protein samples (different aliquotes from the same protein bench) for each measurement with new ligand
Blinding	blinding was not used

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

portfolio reporting summar	ומנטות	Du+1 FD -
rtfolio reporti		5
olio reporti	Ξ	7
reporti		<u>)</u>
_글.	5	2.

Materials & experimental systems		Methods		
n/a	Involved in the study	n/a	Involved in the study	
\boxtimes	Antibodies	\boxtimes	ChIP-seq	
\boxtimes	Eukaryotic cell lines	\boxtimes	Flow cytometry	
\boxtimes	Palaeontology and archaeology	\boxtimes	MRI-based neuroimaging	
\boxtimes	Animals and other organisms			
\boxtimes	Clinical data			
\boxtimes	Dual use research of concern			